bluebird bio, Inc. (BLUE)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 23, 2025

$7.87

P/E Ratio

N/A

Market Cap

$76.51M

Description

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Metrics

Overview

  • HQSomerville, MA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerBLUE
  • Price$7.87+0.38%

Trading Information

  • Market cap$76.51M
  • Float99.12%
  • Average Daily Volume (1m)229,657
  • Average Daily Volume (3m)5,179,800
  • EPS-$35.97

Company

  • Revenue$53.12M
  • Rev growth (1yr)-14.36%
  • Net income-$60.81M
  • Gross margin-83.31%
  • EBITDA margin-459.52%
  • EBITDA-$48.76M
  • EV$390.74M
  • EV/Revenue7.36
  • P/EN/A
  • P/S1.44
  • P/BN/A
Documents
SEC Filings
8-K (2024-12-13)
8-K (2024-12-04)
8-K (2024-11-14)
8-K (2024-11-06)
8-K (2024-10-04)
8-K (2024-09-24)
8-K (2024-09-23)
8-K (2024-08-30)
8-K (2024-08-23)
8-K (2024-08-14)
8-K (2024-07-11)
8-K (2024-06-24)
8-K (2024-05-29)
8-K (2024-05-09)
8-K (2024-05-03)
8-K (2024-04-26)
8-K (2024-04-16)
8-K (2024-03-26)
8-K (2024-03-18)
8-K (2024-01-08)
8-K (2024-01-04)
8-K (2023-12-20)
8-K (2023-12-18)
8-K (2023-12-14)
8-K (2023-12-11)
8-K (2023-11-07)
8-K (2023-10-30)
8-K (2023-09-27)
8-K (2023-08-08)
8-K (2023-07-12)
8-K (2023-06-20)
8-K (2023-06-12)
8-K (2023-05-09)
8-K (2023-03-29)
8-K (2023-01-19)
8-K (2023-01-09)
8-K (2023-01-06)
8-K (2023-01-03)
10-Q (2024-11-14)
10-Q (2024-09-27)
10-Q (2024-09-13)
10-Q (2023-11-07)
10-Q (2023-08-08)
10-Q (2023-05-09)
10-K (2024-09-13)
10-K (2023-03-29)
Wikipedia
Bluebird_bio
Factset Street Account
StreetAccount Earnings Call Q&A Summary: bluebird bio Q3 (2023-11-09T10:18:16Z)
bluebird bio to present new and updated data from gene therapy programs in sickle cell disease and beta-thalassemia at the 65th ASH Annual Meeting and Exposition ($2.94, 0.00) (2023-11-02T13:39:19Z)
bluebird bio reports Q3 EPS ($0.66) vs FactSet ($0.67) [14 est, ($0.83)-(0.51)] - 8-K ($3.30, 0.00) (2023-11-07T12:05:00Z)
bluebird bio initiated neutral at Cantor Fitzgerald ($2.80, 0.00) (2023-10-17T09:57:35Z)
bluebird bio enters into agreement to sell Priority Review Voucher, if approved, for $103M ($2.73, 0.00) (2023-10-30T12:08:47Z)
bluebird bio enters into accounts receivable factoring agreement with Alterna Capital Solutions - 8-K ($3.05, 0.00) (2023-12-18T21:51:51Z)
Earnings Calls
Earnings Report 2024Q3
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-11-07)
Earnings Report (2023-08-08)
Factset
Factset Business Description